Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:856-861

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lim, P. O.
Right arrow Articles by MacDonald, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, P. O.
Right arrow Articles by MacDonald, T. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*FLUDROCORTISONE
*SODIUM CHLORIDE
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Electrocardiology
Right arrow Clinical Studies
Right arrow Other etiology
Right arrow Echocardiography

(Hypertension. 2001;37:856.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Adverse Cardiac Effects of Salt With Fludrocortisone in Hypertension

Pitt O. Lim; Colin A. J. Farquharson; Paul Shiels; Roland T. Jung; Allan D. Struthers; Thomas M. MacDonald

From the Hypertension Research Center, Cardiovascular Research Group, Department of Clinical Pharmacology and Therapeutics (C.A.J.F., A.D.S.), and Department of Endocrinology and Diabetes (R.T.J.), Ninewells Hospital and Medical School, University of Dundee (UK).

The effect of salt on blood pressure (BP) is controversial. A more important question is whether salt can produce cardiac target-organ damage, irrespective of its effect on BP. We assessed the effect of salt with fludrocortisone on QT dispersion and echocardiographic left ventricular diastolic function in a prospective interventional study involving 29 hypertensive subjects with a raised aldosterone/renin ratio who were hospitalized for investigation of possible primary aldosteronism. Each subject over 4 days was given a total of 28.8 g (480 mmol) of sodium chloride and 1.5 mg of fludrocortisone with potassium supplementation. Baseline and posttreatment 12-lead ECGs and echocardiograms were obtained. There were no significant changes in body weight, pulse rate, or BP after treatment with salt and fludrocortisone. Plasma sodium was significantly increased from 141.4 (SD 2.1) to 142.6 (SD 2.4) mmol/L (P=0.001). QT and QTc dispersion both significantly increased: +19.6 (SD 16.5) ms (95% CI, 13.4 to 25.9) (P<0.001) and +19.8 (SD 20.9) ms (95% CI, 11.8 to 27.7) (P<0.001), respectively. There were no significant changes in (n=15) left ventricular dimensions or systolic function, but all diastolic filling indexes, including the preload-independent index, flow propagation velocity (55.49 [SD 10.91] to 48.96 [SD 11.40] cm/s, P=0.018) worsened, suggesting significant deterioration of left ventricular diastolic function with salt and fludrocortisone. In conclusion, a combination of salt with fludrocortisone increased QT dispersion and impaired left ventricular diastolic relaxation in hypertensive patients with high aldosterone/renin ratios. This raises the possibility that salt may have BP-independent adverse cardiac effects in susceptible hypertensive subjects.


Key Words: sodium • fludrocortisone • hypertension • QT dispersion • diastole




This article has been cited by other articles:


Home page
HypertensionHome page
N. Tzemos, P. O. Lim, S. Wong, A. D. Struthers, and T. M. MacDonald
Adverse Cardiovascular Effects of Acute Salt Loading in Young Normotensive Individuals
Hypertension, June 1, 2008; 51(6): 1525 - 1530.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Maitland, L. Bridges, W. P. Davis, J. Loscalzo, and M. A. Pointer
Different Effects of Angiotensin Receptor Blockade on End-Organ Damage in Salt-Dependent and Salt-Independent Hypertension
Circulation, August 29, 2006; 114(9): 905 - 911.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Mulatero, A. Milan, F. Fallo, G. Regolisti, F. Pizzolo, C. Fardella, L. Mosso, L. Marafetti, F. Veglio, and M. Maccario
Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2618 - 2623.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Ouvrard-Pascaud, Y. Sainte-Marie, J.-P. Benitah, R. Perrier, C. Soukaseum, A. N. D. Cat, A. Royer, K. Le Quang, F. Charpentier, S. Demolombe, et al.
Conditional Mineralocorticoid Receptor Expression in the Heart Leads to Life-Threatening Arrhythmias
Circulation, June 14, 2005; 111(23): 3025 - 3033.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
B. Pitt, C. T Stier Jr, and S. Rajagopalan
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 164 - 168.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. C. White
Aldosterone: Direct Effects on and Production by the Heart
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2376 - 2383.
[Full Text] [PDF]


Home page
HypertensionHome page
R. Holland and P. O. Lim
Adverse Cardiac Effects of Salt With Fludrocortisone in Hypertension Response
Hypertension, October 1, 2001; 38 (4): e25 - e25.
[Full Text] [PDF]